Intended use Automated chromogenic assay for the quantitative determination of Antithrombin in human citrated plasma on the IL Coagulation Systems. Summary and principle Antithrombin (AT) or Heparin Cofactor I is the major inhibitor of blood coagulation and is essential for effective heparin therapy. By inhibiting the coagulation proteases, especially thrombin, FXa and FIXa, AT prevents uncontrolled coagulation and thrombosis. Antithrombin deficiency is associated with a high risk of thromboembolic disorders.1,2,3 Liquid Antithrombin can be used to exclude or diagnose hereditary deficiency4,5 in patients with a tendency toward thromboembolism, in pre-operative stages, before prescription of oral contraceptives, DIC,6 nephrotic syndromes, liver diseases7 and in therapy with heparin or antithrombin concentrates.8,9 The Liquid Antithrombin kit is an assay based on a synthetic chromogenic substrate and on FXa inactivation.10,11 As a consequence, the method is specific and not influenced by Heparin Cofactor II. Antithrombin levels in patient plasma are measured automatically on IL Coagulation Systems in two stages: 1. Incubation of the plasma with the Factor Xa reagent in the presence of an excess of heparin. 2. Quantification of the residual FXa activity with a synthetic chromogenic substrate. The paranitroaniline released is monitored kinetically at 405 nm and is inversely proportional to the Antithrombin level in the test sample.

Intended use Automated chromogenic assay for the quantitative determination of Antithrombin in human citrate plasma on the IL Coagulation Systems. Summary and principle Antithrombin (AT) or Heparin Cofactor I is the major inhibitor of blood coagulation and is essential for effective heparin therapy. By inhibiting the coagulation proteases, especially thrombin, FXa and FIXa, AT prevents uncontrolled coagulation and thrombosis. Antithrombin deficiency is associated with a high risk of thromboembolic disorders.1,2,3 Liquid Antithrombin can be used to exclude or diagnose hereditary deficiency4,5 in patients with a tendency towards thromboembolism, in pre-operative stages, before prescription of oral contraceptives, DIC,6 nephrotic syndromes, liver diseases7 and in therapy with heparin or antithrombin concentrates.8,9 The Liquid Antithrombin kit is an assay based on a synthetic chromogenic substrate and on FXa inactivation.10,11 As a consequence, the method is specific and not influenced by Heparin Cofactor II. Antithrombin levels in patient plasma are measured automatically on IL Coagulation Systems in two internships: 1. Incubation of the plasma with the Factor Xa reagent in the presence of an excess of heparin. 2. Quantification of the residual FXa activity with a synthetic chromogenic substrate.The paranitroaniline released is monitored kinetically at 405 nm and is inversely proportional to the Antithrombin level in the test sample.